Amphastar Pharmaceuticals, Inc. (AMPH)
USD 24.42
(1.08%)
USD 24.42
(1.08%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 137.54 Million USD | 50.51% |
| 2022 | 91.38 Million USD | 47.12% |
| 2021 | 62.11 Million USD | 5562.35% |
| 2020 | 1.09 Million USD | -97.76% |
| 2019 | 48.93 Million USD | 952.89% |
| 2018 | -5.73 Million USD | -227.28% |
| 2017 | 4.5 Million USD | -57.2% |
| 2016 | 10.53 Million USD | 477.9% |
| 2015 | -2.78 Million USD | 73.95% |
| 2014 | -10.69 Million USD | -190.2% |
| 2013 | 11.86 Million USD | -34.44% |
| 2012 | 18.09 Million USD | 133.41% |
| 2011 | 7.75 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 43.17 Million USD | 19.38% |
| 2024 Q2 | 37.94 Million USD | -12.11% |
| 2023 Q2 | 26.12 Million USD | 0.35% |
| 2023 Q3 | 49.22 Million USD | 88.42% |
| 2023 Q4 | 36.16 Million USD | -26.52% |
| 2023 Q1 | 26.03 Million USD | -23.24% |
| 2023 FY | 137.54 Million USD | 50.51% |
| 2022 Q4 | 33.91 Million USD | 113.64% |
| 2022 Q1 | 24.25 Million USD | 22.74% |
| 2022 Q2 | 17.34 Million USD | -28.48% |
| 2022 Q3 | 15.87 Million USD | -8.49% |
| 2022 FY | 91.38 Million USD | 47.12% |
| 2021 Q1 | 5.04 Million USD | 180.36% |
| 2021 Q4 | 19.76 Million USD | -33.13% |
| 2021 Q3 | 29.54 Million USD | 280.43% |
| 2021 FY | 62.11 Million USD | 5562.35% |
| 2021 Q2 | 7.76 Million USD | 54.08% |
| 2020 Q4 | -6.27 Million USD | -260.07% |
| 2020 Q2 | -192 Thousand USD | -104.86% |
| 2020 Q3 | 3.91 Million USD | 2141.15% |
| 2020 FY | 1.09 Million USD | -97.76% |
| 2020 Q1 | 3.94 Million USD | 484.89% |
| 2019 Q1 | 868 Thousand USD | -53.51% |
| 2019 Q3 | 1.31 Million USD | -97.26% |
| 2019 FY | 48.93 Million USD | 952.89% |
| 2019 Q4 | -1.02 Million USD | -178.32% |
| 2019 Q2 | 47.78 Million USD | 5405.41% |
| 2018 Q2 | -2.79 Million USD | 61.5% |
| 2018 FY | -5.73 Million USD | -227.28% |
| 2018 Q4 | 1.86 Million USD | -21.85% |
| 2018 Q3 | 2.38 Million USD | 185.63% |
| 2018 Q1 | -7.24 Million USD | -593.6% |
| 2017 Q1 | 893 Thousand USD | 132.57% |
| 2017 Q4 | 1.46 Million USD | 738.86% |
| 2017 Q3 | 175 Thousand USD | -91.13% |
| 2017 Q2 | 1.97 Million USD | 120.83% |
| 2017 FY | 4.5 Million USD | -57.2% |
| 2016 FY | 10.53 Million USD | 477.9% |
| 2016 Q4 | -2.74 Million USD | -170.49% |
| 2016 Q3 | 3.89 Million USD | -43.58% |
| 2016 Q2 | 6.89 Million USD | 177.02% |
| 2016 Q1 | 2.48 Million USD | -66.96% |
| 2015 Q1 | -665 Thousand USD | 73.62% |
| 2015 FY | -2.78 Million USD | 73.95% |
| 2015 Q4 | 7.53 Million USD | 350.43% |
| 2015 Q3 | -3 Million USD | 54.75% |
| 2015 Q2 | -6.64 Million USD | -899.55% |
| 2014 Q1 | -1.61 Million USD | -188.52% |
| 2014 Q2 | -1.18 Million USD | 27.12% |
| 2014 FY | -10.69 Million USD | -190.2% |
| 2014 Q4 | -2.52 Million USD | 53.13% |
| 2014 Q3 | -5.37 Million USD | -355.85% |
| 2013 FY | 11.86 Million USD | -34.44% |
| 2013 Q1 | 2.38 Million USD | -45.39% |
| 2013 Q2 | 7.81 Million USD | 227.88% |
| 2013 Q3 | -159 Thousand USD | -102.04% |
| 2013 Q4 | 1.82 Million USD | 1250.31% |
| 2012 FY | 18.09 Million USD | 133.41% |
| 2012 Q4 | 4.36 Million USD | 0.0% |
| 2011 FY | 7.75 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 48.15 Million USD | -185.63% |
| Embecta Corp. | 70.4 Million USD | -95.376% |
| ANI Pharmaceuticals, Inc. | 18.77 Million USD | -632.44% |
| Dynavax Technologies Corporation | -6.38 Million USD | 2252.841% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 165.733% |
| Pacira BioSciences, Inc. | 41.95 Million USD | -227.839% |
| PainReform Ltd. | -9.34 Million USD | 1572.014% |
| Aquestive Therapeutics, Inc. | -7.87 Million USD | 1847.713% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | 3152.456% |
| SCYNEXIS, Inc. | 67.04 Million USD | -105.165% |
| China SXT Pharmaceuticals, Inc. | -3.09 Million USD | 4539.038% |
| Cosmos Health Inc. | -18.54 Million USD | 841.776% |
| Journey Medical Corporation | -3.85 Million USD | 3669.816% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | 3152.456% |
| Safety Shot Inc | -15.08 Million USD | 1011.918% |
| Alpha Teknova, Inc. | -36.78 Million USD | 473.967% |
| Intra-Cellular Therapies, Inc. | -139.67 Million USD | 198.476% |
| Bright Green Corporation | -13.12 Million USD | 1147.751% |
| Procaps Group, S.A. | 42.54 Million USD | -223.331% |
| Theratechnologies Inc. | -23.95 Million USD | 674.133% |
| Harrow Health, Inc. | -24.41 Million USD | 663.455% |
| Sonoma Pharmaceuticals, Inc. | -4.83 Million USD | 2944.778% |
| Biofrontera Inc. | -20.13 Million USD | 783.25% |
| DURECT Corporation | -27.62 Million USD | 597.918% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | -10351.748% |
| Cronos Group Inc. | -73.96 Million USD | 285.965% |
| OptiNose, Inc. | -35.48 Million USD | 487.636% |
| Ironwood Pharmaceuticals, Inc. | -1 Billion USD | 113.724% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 425.944% |
| RedHill Biopharma Ltd. | 23.91 Million USD | -475.117% |
| Organogenesis Holdings Inc. | 4.94 Million USD | -2681.496% |
| Guardion Health Sciences, Inc. | 158.03 Thousand USD | -86935.619% |
| Cumberland Pharmaceuticals Inc. | -6.27 Million USD | 2290.444% |
| Radius Health, Inc. | -25.79 Million USD | 633.306% |
| Universe Pharmaceuticals INC | -6.16 Million USD | 2331.764% |
| ProPhase Labs, Inc. | -16.78 Million USD | 919.598% |
| Phibro Animal Health Corporation | 2.41 Million USD | -5593.088% |
| Procaps Group S.A. | 42.54 Million USD | -223.331% |
| Alvotech | -551.73 Million USD | 124.93% |
| TherapeuticsMD, Inc. | -10.27 Million USD | 1438.247% |
| Viatris Inc. | 54.7 Million USD | -151.453% |
| Rockwell Medical, Inc. | -8.43 Million USD | 1729.873% |
| Aytu BioPharma, Inc. | -15.84 Million USD | 968.12% |
| SIGA Technologies, Inc. | 68.06 Million USD | -102.068% |
| Tilray Brands, Inc. | -244.98 Million USD | 156.145% |
| Lifecore Biomedical, Inc. | 12.01 Million USD | -1044.968% |
| Shineco, Inc. | -22.44 Million USD | 712.699% |
| PetIQ, Inc. | 2.13 Million USD | -6354.481% |
| Regencell Bioscience Holdings Limited | -4.3 Million USD | 3297.355% |
| Incannex Healthcare Limited | -18.45 Million USD | 845.138% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 44.916% |
| Alimera Sciences, Inc. | -20.13 Million USD | 783.216% |
| Silver Spike Investment Corp. | 7.34 Million USD | -1773.883% |
| Assertio Holdings, Inc. | -331.94 Million USD | 141.436% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6.59 Million USD | 2186.315% |
| Petros Pharmaceuticals, Inc. | -8.16 Million USD | 1784.942% |
| Clever Leaves Holdings Inc. | -17.89 Million USD | 868.451% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 785.76% |
| Avadel Pharmaceuticals plc | -160.27 Million USD | 185.818% |
| Hempacco Co., Inc. | -13.12 Million USD | 1147.876% |
| Talphera, Inc. | -18.39 Million USD | 847.649% |
| Alvotech | -551.73 Million USD | 124.93% |
| Eagle Pharmaceuticals, Inc. | 35.64 Million USD | -285.907% |
| Lantheus Holdings, Inc. | 326.66 Million USD | 57.894% |
| Currenc Group, Inc. | -15.3 Million USD | 998.602% |
| Kamada Ltd. | 8.28 Million USD | -1560.369% |
| Indivior PLC | 2 Million USD | -6777.25% |
| Evoke Pharma, Inc. | -7.79 Million USD | 1865.141% |
| Flora Growth Corp. | -57.03 Million USD | 341.155% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 785.76% |
| Evolus, Inc. | -61.68 Million USD | 322.98% |
| HUTCHMED (China) Limited | 100.78 Million USD | -36.48% |
| Akanda Corp. | -32.27 Million USD | 526.165% |